Vivos Therapeutics to Participate at the Benzinga Healthcare Small Cap Conference

Eufemia Didonato

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

HIGHLANDS RANCH, Colo., Sept. 22, 2021 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (OSA), today announced that Vivos’ Chairman and Chief Executive Officer, Kirk Huntsman, and Vivos’ Chief Financial Officer, Brad Amman, will be presenting at the online Benzinga Healthcare Small Cap Conference at 2:20 pm EST on Wednesday, September 29, 2021. The Benzinga Healthcare Small Cap Conference will be taking place from September 29-30, 2021.

Investors interested in joining the Vivos presentation can register for a free spectator pass at the link below:

Healthcare: September 29-30

A replay of the presentation will be available for view following the presentation on Vivos’ website at:

About Vivos Therapeutics, Inc.

Vivos Therapeutics Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for adult patients suffering from mild-to-moderate obstructive sleep apnea (OSA). The Vivos treatment involves customized oral appliances and treatment protocols called the Vivos System. Vivos believes that its Vivos System oral appliance technology represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for adults with mild-to-moderate OSA. Vivos also sells orthodontic appliances for adults and children. Vivos’ oral appliances have proven effective in over 19,000 patients treated worldwide by more than 1,250 trained dentists.

Combining proprietary technologies and protocols that alter the size, shape and position of the tissues that comprise a patient’s upper airway, the Vivos System opens airway space and may significantly reduce symptoms and conditions associated with mild-to-moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes VivosScore, powered by the SleepImage diagnostic technology, for Home Sleep Testing in adults and children. The Vivos Integrated Practice (VIP) program offers dentists training and other value-added services in connection with using the Vivos System.

For more information, visit

About the Benzinga Healthcare Small Cap Conference

The Benzinga Healthcare Small Cap Conference bridges the gap between Small Cap companies, investors, and traders. Learn about small cap investing with clearly defined Educational Modules, take a look at a curated group of Small Cap investment opportunities, and connect with the healthcare Small Cap audience in an intimate, virtual setting.

For more information and/or to register for the conference please visit:

Cautionary Note Regarding Forward-Looking StatementsThis press release, the management presentation discussed herein, and statements of the Company’s management made in connection therewith contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events, particularly with respect to the public offering described herein. Words such as “may”, “should”, “expects”, “projects,” “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates” and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the risk factors described in Vivos’ filings with the Securities and Exchange Commission (“SEC”). Vivos’ filings can be obtained free of charge on the SEC’s website at Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos’ expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based.

Investor Relations Contact:Edward LoewInvestor Relations Officer(602) [email protected]

Media Relations Contact:Caitlin Kasunich / Jenny RoblesKCSA Strategic Communications(212) 896-1241 / (917) [email protected] / [email protected]

Primary Logo

Source: Vivos Therapeutics, Inc

Source Article

Next Post

Marijuana jobs are becoming a refuge for retail and restaurant workers

In this photo taken March 24, 2020, Christopher Ellis, right, leans in to show his identification to budtender Maegan Clark, left, as he stands on a line taped on the floor to designate a social distancing separation while shopping at The Reef Capitol Hill, a marijuana store in Seattle. (AP […]